Heron Therapeutics Inc
HRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$92.9M
Close$
$3.67
997.3% upside
Current Fair Value
997.3% upsideUndervalued by 997.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $92.90 Million |
|---|---|
| Enterprise Value | $208.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.65 |
| Outstanding Shares | 189,646,000 |
Return
| Return on Equity | -338.63% |
|---|---|
| Return on Assets | -12.57% |
| Return on Invested Capital | -8.39% |
Valuation & Multiples
| P/E Ratio | -2.77 |
|---|---|
| PEG | 0.68 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.38 |
| Enterprise Value to EBIT | -15.96 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.68 |
| Debt to Equity | 15.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 189.88% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.17%▼ 69.55% |
|---|---|
| Total Invested | $10.95M▼ 91.29% |
| Investors Holding | 66▼ 107.00% |
ESG Score
No data
About Heron Therapeutics Inc
CEO: Barry Quart